Mindset Pharma Inc.
CSE: MSET
Company Overview
Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. The company is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.
The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$0.27
Diluted EPS (ttm)
Management Team
Mr. James Andre-Charles Lanthier
Chief Exec. Officer
Mr. Arvin Ramos CPA
Chief Financial Officer
Mr. Joseph Araujo
Chief Scientific Officer, Member of Scientific Advisory Board & Director
Mr. Jason Atkinson
VP of Corp. Devel.
Dr. Abdelmalik Slassi Ph.D.
Sr. VP of Innovation & Member of Scientific Advisory Board
Dr. Fiona Randall B.Sc., Ph.D.
Sr. VP of External Alliances & Scientific Strategy
Chris Irwin
Corp. Sec.
Key Highlights
Market Capitalization
$21,415,641
Shares Outstanding
66,140,789
Shares Short (% of Float)
()
Insider Ownership
12%